{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T17:13:19Z","timestamp":1792602799815,"version":"4.5.0"},"reference-count":94,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2024,9,20]],"date-time":"2024-09-20T00:00:00Z","timestamp":1726790400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Jeju National University"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Marine Drugs"],"abstract":"<jats:p>Marine natural products comprise unique chemical structures and vast varieties of biological activities. This review aims to summarize halichondrin, a marine natural product, and its synthetic analogs along with its therapeutic properties and mechanisms. Halichondrin and its analogs, derived from marine sponges, exhibit potent antineoplastic properties, making them promising candidates for cancer therapeutics. These compounds, characterized by their complex molecular structures, have demonstrated significant efficacy in inhibiting microtubule dynamics, leading to cell cycle arrest and apoptosis in various cancer cell lines. Several types of halichondrins such as halichondrins B, C, norhalichondrin B, and homohalichondrin B have been discovered with similar anticancer and antitumor characteristics. Since naturally available halichondrins show hurdles in synthesis, recent advancements in synthetic methodologies have enabled the development of several halichondrin analogs, such as E7389 (eribulin), which have shown improved therapeutic indices. Eribulin has shown excellent immunomodulatory properties by several mechanisms such as reprogramming tumor microenvironments, facilitating the infiltration and activation of immune cells, and inhibiting microtubule dynamics. Despite promising results, challenges remain in the synthesis and clinical application of these compounds. This review explores the mechanisms underlying the immunomodulatory activity of halichondrin and its analogs in cancer therapy, along with their clinical applications and potential for future drug development.<\/jats:p>","DOI":"10.3390\/md22090426","type":"journal-article","created":{"date-parts":[[2024,9,20]],"date-time":"2024-09-20T10:49:48Z","timestamp":1726829388000},"page":"426","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Immunomodulatory Effects of Halichondrin Isolated from Marine Sponges and Its Synthetic Analogs in Oncological Applications"],"prefix":"10.3390","volume":"22","author":[{"given":"Dinusha Shiromala","family":"Dissanayake","sequence":"first","affiliation":[{"name":"Department of Marine Life Sciences, School of Marine Biomedical Sciences, Jeju National University, Jeju 63243, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9603-4904","authenticated-orcid":false,"given":"Dineth Pramuditha","family":"Nagahawatta","sequence":"additional","affiliation":[{"name":"Department of Marine Life Sciences, School of Marine Biomedical Sciences, Jeju National University, Jeju 63243, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jung-Suck","family":"Lee","sequence":"additional","affiliation":[{"name":"Department of Seafood Science and Technology, Institute of Marine Industry, Gyeongsang National University, Tongyeong 53064, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3299-7266","authenticated-orcid":false,"given":"You-Jin","family":"Jeon","sequence":"additional","affiliation":[{"name":"Department of Marine Life Sciences, School of Marine Biomedical Sciences, Jeju National University, Jeju 63243, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,9,20]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1039\/D0NP00089B","article-title":"Marine natural products","volume":"38","author":"Carroll","year":"2021","journal-title":"Nat. Prod. Rep."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1351\/pac198658050701","article-title":"Halichondrins-Antitumor Polyether Macrolides from a Marine Sponge","volume":"58","author":"Hirata","year":"1986","journal-title":"Pure Appl. Chem."},{"key":"ref_3","first-page":"341","article-title":"Aspekte des Massentransfers bei der Verwertung von Kohlenwasserstoffen durch Hefe","volume":"36","author":"Katinger","year":"2008","journal-title":"Pathol. Microbiol."},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"\u00d6zenver, N., and Efferth, T. (2021). Mitosis Inhibitors and Medicinal Plants: Neurotoxicity and Neuroprotection. Medicinal Herbs and Fungi: Neurotoxicity vs. Neuroprotection, Springer.","DOI":"10.1007\/978-981-33-4141-8_1"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"2607","DOI":"10.1002\/9781119143802.ch117","article-title":"Marine-derived Pharmaceuticals for Oncotherapy: Clinical Trial and FDA-approved Compounds","volume":"4","author":"Prabhu","year":"2020","journal-title":"Encycl. Mar. Biotechnol."},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Strzelec, M., Detka, J., Mieszczak, P., Sobocinska, M.K., and Majka, M. (2023). Immunomodulation-a general review of the current state-of-the-art and new therapeutic strategies for targeting the immune system. Front. Immunol., 14.","DOI":"10.3389\/fimmu.2023.1127704"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1016\/j.annonc.2020.03.285","article-title":"Autoimmune diseases and immune-checkpoint inhibitors for cancer therapy: Review of the literature and personalized risk-based prevention strategy","volume":"31","author":"Haanen","year":"2020","journal-title":"Ann. Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Hart, J.B., Lill, R.E., Hickford, S.J., Blunt, J.W., and Munro, M.H. (2000). The halichondrins: Chemistry, biology, supply and delivery. Drugs from the Sea, Karger Publishers.","DOI":"10.1159\/000062488"},{"key":"ref_9","unstructured":"Hart, J.B. (2024, September 16). Studies on Marine Natural Products. Available online: https:\/\/ir.canterbury.ac.nz\/items\/10817622-e16b-4f12-8874-7d2883ab9331."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"9267","DOI":"10.1021\/jacs.1c05270","article-title":"A reverse approach to the total synthesis of halichondrin B","volume":"143","author":"Nicolaou","year":"2021","journal-title":"J. Am. Chem. Soc."},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Bai, R., Smith, A.B., Pettit, G.R., and Hamel, E. (2022). The interaction of spongistatin 1 with tubulin. Arch. Biochem. Biophys., 727.","DOI":"10.1016\/j.abb.2022.109296"},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Davey, S. (2012). The halichondrin C campaign. Nat. Chem., 4.","DOI":"10.1038\/nchem.1287"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1021\/ja2108307","article-title":"Total synthesis of halichondrin C","volume":"134","author":"Yamamoto","year":"2012","journal-title":"J. Am. Chem. Soc."},{"key":"ref_14","unstructured":"Hanson, G.H. (2006). Synthetic Studies of Halichondrin B Subunits. [Ph.D. Thesis, The University of Wisconsin]."},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Cermak, V., Dostal, V., Jelinek, M., Libusova, L., Kovar, J., Rosel, D., and Brabek, J. (2020). Microtubule-targeting agents and their impact on cancer treatment. Eur. J. Cell Biol., 99.","DOI":"10.1016\/j.ejcb.2020.151075"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1007\/s40495-023-00313-3","article-title":"Drug Discovery from Natural Sources","volume":"9","author":"Newman","year":"2023","journal-title":"Curr. Pharmacol. Rep."},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Nicolaou, K.C., Pan, S., Shelke, Y., Rigol, S., Bao, R., Das, D., and Ye, Q. (2022). A unified strategy for the total syntheses of eribulin and a macrolactam analogue of halichondrin B. Proc. Natl. Acad. Sci. USA, 119.","DOI":"10.1073\/pnas.2208938119"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"20970","DOI":"10.1021\/jacs.1c10539","article-title":"A highly convergent total synthesis of norhalichondrin B","volume":"143","author":"Nicolaou","year":"2021","journal-title":"J. Am. Chem. Soc."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"942","DOI":"10.2174\/1389557520666200212104742","article-title":"Medicinal Potential of Heterocyclic Compounds from Diverse Natural Sources for the Management of Cancer","volume":"20","author":"Singh","year":"2020","journal-title":"Mini Rev. Med. Chem."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"116","DOI":"10.2174\/2215083808666220817095619","article-title":"A Mini-Review on Marine Bioactive Compounds as a Source of Antiviral Drug Lead","volume":"9","author":"Parmar","year":"2023","journal-title":"Curr. Tradit. Med."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"2837","DOI":"10.1021\/acs.orglett.3c03663","article-title":"Ten-Gram-Scale Total Synthesis of the Anticancer Drug Candidate E7130 to Supply Clinical Trials","volume":"26","author":"Kaburagi","year":"2024","journal-title":"Org. Lett."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"3044","DOI":"10.1021\/cr900016w","article-title":"The halichondrins and E7389","volume":"109","author":"Jackson","year":"2009","journal-title":"Chem. Rev."},{"key":"ref_23","unstructured":"National Center for Biotechnology Information (2024, September 16). PubChem Compound Summary for CID 5488895, Halichondrin B, Available online: https:\/\/pubchem.ncbi.nlm.nih.gov\/compound\/Halichondrin-B."},{"key":"ref_24","unstructured":"National Center for Biotechnology Information (2024, September 16). Pubchem Compounds for CID 57333215, Halichondrin C, Available online: https:\/\/pubchem.ncbi.nlm.nih.gov\/compound\/Halichondrin-C."},{"key":"ref_25","unstructured":"National Center for Biotechnology Information (2024, September 16). PubChem Substance Record for SID 273819388, Norhalichondrin B, Source: Japan Chemical Substance Dictionary (Nikkaji), Available online: https:\/\/pubchem.ncbi.nlm.nih.gov\/substance\/273819388."},{"key":"ref_26","unstructured":"National Center for Biotechnology Information (2024, September 16). PubChem Compound Summary for CID 163705, Homohalichondrin B, Available online: https:\/\/pubchem.ncbi.nlm.nih.gov\/compound\/163705."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"8643","DOI":"10.1016\/S0040-4039(96)01999-5","article-title":"Synthetic studies on halichondrins: A practical synthesis of the C.1\u2013C.13 segment","volume":"37","author":"Stamos","year":"1996","journal-title":"Tetrahedron Lett."},{"key":"ref_28","first-page":"135","article-title":"Clinical Utility of Eribulin Mesylate in the Treatment of Breast Cancer: A Chinese Perspective","volume":"13","author":"Yuan","year":"2021","journal-title":"Breast Cancer"},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Lu, W.Y., Li, H.J., Li, Q.Y., and Wu, Y.C. (2021). Application of marine natural products in drug research. Bioorg. Med. Chem., 35.","DOI":"10.1016\/j.bmc.2021.116058"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1039\/D0NP00060D","article-title":"The quest for supernatural products: The impact of total synthesis in complex natural products medicinal chemistry","volume":"37","author":"Wu","year":"2020","journal-title":"Nat. Prod. Rep."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1158\/1535-7163.MCT-22-0475","article-title":"Liposome-Encapsulated Eribulin Shows Enhanced Antitumor Activity over Eribulin for Combination Therapy with Anti-PD-1 Antibody","volume":"22","author":"Niwa","year":"2023","journal-title":"Mol. Cancer Ther."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.ejca.2022.03.004","article-title":"Phase 1 study of the liposomal formulation of eribulin (E7389-LF): Results from the breast cancer expansion cohort","volume":"168","author":"Masuda","year":"2022","journal-title":"Eur. J. Cancer"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.1021\/acs.oprd.4c00016","article-title":"What Does It Take to Develop Structurally Complex Molecules by Total Synthesis? Rapid Process Development and GMP Manufacturing of E7130 Drug Substance for First-in-Human Clinical Study","volume":"28","author":"Sasaki","year":"2024","journal-title":"Org. Process Res. Dev."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"5302","DOI":"10.1039\/C5OB00169B","article-title":"Design and synthesis of analogues of natural products","volume":"13","author":"Maier","year":"2015","journal-title":"Org. Biomol. Chem."},{"key":"ref_35","unstructured":"Henderson, J.A. (2008). Synthesis of Marine Natural Products: Aburatubolactam A and the Halichondrins. [Ph.D. Thesis, University of Colorado at Boulder]."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1039\/oc9928900249","article-title":"Chapter 9\u2014Synthetic methods","volume":"Volume 89","author":"Lawrence","year":"1992","journal-title":"Annual Reports Section \u201cB\u201d (Organic Chemistry)"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"3990","DOI":"10.1039\/D1QO00481F","article-title":"Structure determination, correction, and disproof of marine macrolide natural products by chemical synthesis","volume":"8","author":"Fuwa","year":"2021","journal-title":"Org. Chem. Front."},{"key":"ref_38","first-page":"227","article-title":"Chapter 14\u2014Case History: Discovery of Eribulin (HALAVEN\u2122), a Halichondrin B Analogue That Prolongs Overall Survival in Patients with Metastatic Breast Cancer","volume":"Volume 46","author":"Macor","year":"2011","journal-title":"Annual Reports in Medicinal Chemistry"},{"key":"ref_39","unstructured":"Kaghad, A. (2024, September 16). Formal Syntheses of Eribulin and Synthesis of Biologically Active Small Molecules. Summit Research Repository, SFU, Canada. Available online: https:\/\/summit.sfu.ca\/item\/36065."},{"key":"ref_40","unstructured":"Quach, R., Aitken, H., and Kishi, Y. (2024, September 16). Stereochemistry and Total Synthesis of Neonorhalichondrin B. Cambridge Open Engage, ChemRxiv. Available online: https:\/\/chemrxiv.org\/engage\/chemrxiv\/article-details\/64b14dedb053dad33a3ac3a1."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1080\/10286020.2023.2249825","article-title":"A review on marine source as anticancer agents","volume":"26","author":"Rai","year":"2024","journal-title":"J. Asian Nat. Prod. Res."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"3139","DOI":"10.2174\/1381612827666210319125652","article-title":"Tumor-Associated Macrophages as Potential Targets for Anti-Cancer Activity of Marine Invertebrate-Derived Compounds","volume":"27","author":"Dolmatova","year":"2021","journal-title":"Curr. Pharm. Des."},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"Salemme, V., Centonze, G., Cavallo, F., Defilippi, P., and Conti, L. (2021). The Crosstalk Between Tumor Cells and the Immune Microenvironment in Breast Cancer: Implications for Immunotherapy. Front. Oncol., 11.","DOI":"10.3389\/fonc.2021.610303"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1111\/cas.12488","article-title":"Eribulin mesylate reduces tumor microenvironment abnormality by vascular remodeling in preclinical human breast cancer models","volume":"105","author":"Funahashi","year":"2014","journal-title":"Cancer Sci."},{"key":"ref_45","doi-asserted-by":"crossref","unstructured":"Ito, K., Hamamichi, S., Abe, T., Akagi, T., Shirota, H., Kawano, S., Asano, M., Asano, O., Yokoi, A., and Matsui, J. (2017). Eribulin modulates tumor microenvironment through vascular remodeling for antitumor effect in multiple mouse xenograft models. Cancer Res., 77.","DOI":"10.1158\/1538-7445.AM2017-5927"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.ctrv.2018.08.008","article-title":"Multiple modes of action of eribulin mesylate: Emerging data and clinical implications","volume":"70","author":"Cortes","year":"2018","journal-title":"Cancer Treat. Rev."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1158\/1535-7163.MCT-23-0158","article-title":"Amelioration of Tumor-promoting Microenvironment via Vascular Remodeling and CAF Suppression Using E7130: Biomarker Analysis by Multimodal Imaging Modalities","volume":"23","author":"Ito","year":"2024","journal-title":"Mol. Cancer Ther."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"2273","DOI":"10.1111\/cas.13392","article-title":"Antitumor effects of eribulin depend on modulation of the tumor microenvironment by vascular remodeling in mouse models","volume":"108","author":"Ito","year":"2017","journal-title":"Cancer Sci."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1038\/bjc.2014.80","article-title":"Eribulin mesilate suppresses experimental metastasis of breast cancer cells by reversing phenotype from epithelial-mesenchymal transition (EMT) to mesenchymal-epithelial transition (MET) states","volume":"110","author":"Yoshida","year":"2014","journal-title":"Br. J. Cancer"},{"key":"ref_50","first-page":"2929","article-title":"Eribulin Promotes Antitumor Immune Responses in Patients with Locally Advanced or Metastatic Breast Cancer","volume":"38","author":"Goto","year":"2018","journal-title":"Anticancer Res."},{"key":"ref_51","doi-asserted-by":"crossref","unstructured":"Ho, G.Y., Vandenberg, C.J., Lim, R., Christie, E.L., Garsed, D.W., Lieschke, E., Nesic, K., Kondrashova, O., Ratnayake, G., and Radke, M. (2023). The microtubule inhibitor eribulin demonstrates efficacy in platinum-resistant and refractory high-grade serous ovarian cancer patient-derived xenograft models. Ther. Adv. Med. Oncol., 15.","DOI":"10.1177\/17588359231208674"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"5456","DOI":"10.2174\/1381612826666200728141601","article-title":"Recent Advances in Strategies for Extracellular Matrix Degradation and Synthesis Inhibition for Improved Therapy of Solid Tumors","volume":"26","author":"Sandha","year":"2020","journal-title":"Curr. Pharm. Des."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1038\/s41416-019-0556-9","article-title":"Eribulin rapidly inhibits TGF-beta-induced Snail expression and can induce Slug expression in a Smad4-dependent manner","volume":"121","author":"Kaul","year":"2019","journal-title":"Br. J. Cancer"},{"key":"ref_54","doi-asserted-by":"crossref","unstructured":"Pederson, P.J., Liang, H., Filonov, D., and Mooberry, S.L. (2021). Eribulin and Paclitaxel Differentially Alter Extracellular Vesicles and Their Cargo from Triple-Negative Breast Cancer Cells. Cancers, 13.","DOI":"10.3390\/cancers13112783"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"702","DOI":"10.2174\/1871520617666170918142811","article-title":"Antitumor Potential of Marine Natural Products: A Mechanistic Investigation","volume":"18","author":"Hu","year":"2018","journal-title":"Anticancer Agents Med. Chem."},{"key":"ref_56","doi-asserted-by":"crossref","unstructured":"Wen, W., Marcinkowski, E., Luyimbazi, D., Luu, T., Xing, Q., Yan, J., Wang, Y., Wu, J., Guo, Y., and Tully, D. (2019). Eribulin Synergistically Increases Anti-Tumor Activity of an mTOR Inhibitor by Inhibiting pAKT\/pS6K\/pS6 in Triple Negative Breast Cancer. Cells, 8.","DOI":"10.3390\/cells8091010"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1080\/15384101.2020.1716144","article-title":"The microtubule targeting agents eribulin and paclitaxel activate similar signaling pathways and induce cell death predominantly in a caspase-independent manner","volume":"19","author":"Husemann","year":"2020","journal-title":"Cell Cycle"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1124\/molpharm.121.000297","article-title":"Eribulin Activates the cGAS-STING Pathway via the Cytoplasmic Accumulation of Mitochondrial DNA","volume":"100","author":"Fermaintt","year":"2021","journal-title":"Mol. Pharmacol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"2213","DOI":"10.1007\/s12325-020-01613-6","article-title":"Effectiveness of Eribulin in Metastatic Breast Cancer: 10 Years of Real-World Clinical Experience in the United States","volume":"38","author":"Mougalian","year":"2021","journal-title":"Adv. Ther."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"917","DOI":"10.21873\/invivo.11858","article-title":"Eribulin Suppresses New Metastases in Patients With Metastatic Breast Cancer","volume":"34","author":"Fujii","year":"2020","journal-title":"Vivo"},{"key":"ref_61","doi-asserted-by":"crossref","unstructured":"Lee, J.S., Yost, S.E., Blanchard, S., Schmolze, D., Yin, H.H., Pillai, R., Robinson, K., Tang, A., Martinez, N., and Portnow, J. (2019). Phase I clinical trial of the combination of eribulin and everolimus in patients with metastatic triple-negative breast cancer. Breast Cancer Res., 21.","DOI":"10.1186\/s13058-019-1202-4"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"6384","DOI":"10.1158\/1078-0432.CCR-16-2422","article-title":"FDA Approval Summary: Eribulin for Patients with Unresectable or Metastatic Liposarcoma Who Have Received a Prior Anthracycline-Containing Regimen","volume":"23","author":"Osgood","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1080\/13543784.2017.1292250","article-title":"Eribulin in non-small cell lung cancer: Challenges and potential strategies","volume":"26","author":"Swami","year":"2017","journal-title":"Expert. Opin. Investig. Drugs"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1007\/s00280-015-2868-7","article-title":"Pharmacodynamics (PD) and pharmacokinetics (PK) of E7389 (eribulin, halichondrin B analog) during a phase I trial in patients with advanced solid tumors: A California Cancer Consortium trial","volume":"76","author":"Morgan","year":"2015","journal-title":"Cancer Chemother. Pharmacol."},{"key":"ref_65","doi-asserted-by":"crossref","unstructured":"Jiang, M., Shao, B., Wan, D., Liu, J., He, M., Chai, Y., Sang, D., Wang, J., Ma, F., and Fan, Y. (2023). Eribulin combined with antiangiogenic agents in women with HER2-negative metastatic breast cancer: A retrospective multicenter study. Ther. Adv. Med. Oncol., 15.","DOI":"10.1177\/17588359231204856"},{"key":"ref_66","doi-asserted-by":"crossref","unstructured":"Terashima, M., Sakai, K., Togashi, Y., Hayashi, H., De Velasco, M.A., Tsurutani, J., and Nishio, K. (2014). Synergistic antitumor effects of S-1 with eribulin in vitro and in vivo for triple-negative breast cancer cell lines. Springerplus, 3.","DOI":"10.1186\/2193-1801-3-417"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"4031","DOI":"10.21873\/anticanres.13559","article-title":"The Effects of Eribulin on Breast Cancer Microenvironment Identified Using Eribulin-resistant Breast Cancer Cell Lines","volume":"39","author":"Goto","year":"2019","journal-title":"Anticancer Res."},{"key":"ref_68","first-page":"509","article-title":"In vitro radiosensitization by eribulin in human cancer cell lines","volume":"27","author":"Benlloch","year":"2022","journal-title":"Rep. Pract. Oncol. Radiother."},{"key":"ref_69","doi-asserted-by":"crossref","unstructured":"Hsu, C.Y., Yanagi, T., Maeda, T., Nishihara, H., Miyamoto, K., Kitamura, S., Tokuchi, K., and Ujiie, H. (2023). Eribulin inhibits growth of cutaneous squamous cell carcinoma cell lines and a novel patient-derived xenograft. Sci. Rep., 13.","DOI":"10.1038\/s41598-023-35811-3"},{"key":"ref_70","first-page":"5698","article-title":"Suppression of alpha-tubulin acetylation potentiates therapeutic efficacy of Eribulin in liver cancer","volume":"13","author":"Zhong","year":"2023","journal-title":"Am. J. Cancer Res."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.21873\/invivo.12534","article-title":"Efficacy of Oral Recombinant Methioninase and Eribulin on a PDOX Model of Triple-negative Breast Cancer (TNBC) Liver Metastasis","volume":"35","author":"Lim","year":"2021","journal-title":"Vivo"},{"key":"ref_72","doi-asserted-by":"crossref","unstructured":"Wu, H.C., Zhu, K.Y., Tu, X.L., Albu, D., Woodall-Jappe, M., and Littlefield, B.A. (2020). Evaluation of eribulin-induced alterations of the intact immune cell landscape in spleens and tumors from tumor-bearing immunocompetent mice. Cancer Res., 80.","DOI":"10.1158\/1538-7445.AM2020-5522"},{"key":"ref_73","doi-asserted-by":"crossref","unstructured":"Synold, T.W., Morgan, R.J., Newman, E.M., Lenz, H.J., Gandara, D.R., Colevas, A.D., Lewis, M.D., and Doroshow, J.H. (2005). A phase I pharmacokinetic and target validation study of the novel anti-tubulin agent E7389: A California Cancer Consortium trial. J. Clin. Oncol., 23.","DOI":"10.1200\/jco.2005.23.16_suppl.3036"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/S1359-6349(08)72380-2","article-title":"446 POSTER A phase I study of eribulin mesylate (E7389) in patients with refractory cancers","volume":"6","author":"Minami","year":"2008","journal-title":"Eur. J. Cancer Suppl."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"4073","DOI":"10.21873\/anticanres.12697","article-title":"Phase II Clinical Trial of First-line Eribulin Plus Trastuzumab for Advanced or Recurrent HER2-positive Breast Cancer","volume":"38","author":"Sakaguchi","year":"2018","journal-title":"Anticancer Res."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1097\/COC.0000000000000526","article-title":"Phase II Trial of Eribulin in Patients With Metastatic Hormone Refractory Prostate Cancer: A Trial of the ECOG-ACRIN Cancer Research Group (E5805)","volume":"42","author":"Stein","year":"2019","journal-title":"Am. J. Clin. Oncol."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1093\/annonc\/mdr444","article-title":"A phase II study of eribulin in Japanese patients with heavily pretreated metastatic breast cancer","volume":"23","author":"Aogi","year":"2012","journal-title":"Ann. Oncol."},{"key":"ref_78","doi-asserted-by":"crossref","unstructured":"Hayashida, T., Jinno, H., Mori, K., Sato, H., Matsui, A., Sakurai, T., Hattori, H., Takayama, S., Wada, M., and Takahashi, M. (2018). Phase II trial of eribulin mesylate as a first- or second-line treatment for locally advanced or metastatic breast cancer: A multicenter, single-arm trial. BMC Cancer, 18.","DOI":"10.1186\/s12885-018-4628-7"},{"key":"ref_79","doi-asserted-by":"crossref","unstructured":"Szeja, W., and Grynkiewicz, G. (2018). Syntheses of asymmetrically substituted pyrans of natural origin. Nat. Prod. Source Mol. Ther. Potential Res. Dev. Chall. Perspect., 233\u2013307.","DOI":"10.1007\/978-3-030-00545-0_7"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"3297","DOI":"10.1021\/acs.chemrev.0c00383","article-title":"Challenges and Opportunities in Cancer Drug Resistance","volume":"121","author":"Ward","year":"2021","journal-title":"Chem. Rev."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"500","DOI":"10.21873\/invivo.13466","article-title":"Risk Factors for Eribulin-induced Severe Neutropenia in Patients With Recurrent Breast Cancer","volume":"38","author":"Takada","year":"2024","journal-title":"Vivo"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"3693","DOI":"10.21873\/anticanres.15858","article-title":"Risk Factor Analysis for the Occurrence of Severe Adverse Effects in Eribulin Treatment","volume":"42","author":"Saito","year":"2022","journal-title":"Anticancer Res."},{"key":"ref_83","doi-asserted-by":"crossref","unstructured":"Tarasiuk, O., Cavaletti, G., and Meregalli, C. (2022). Clinical and preclinical features of eribulin-related peripheral neuropathy. Exp. Neurol., 348.","DOI":"10.1016\/j.expneurol.2021.113925"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"293","DOI":"10.2217\/epi-2023-0339","article-title":"Alteration of DNA methyltransferases by eribulin elicits broad DNA methylation changes with potential therapeutic implications for triple-negative breast cancer","volume":"16","author":"Bagheri","year":"2024","journal-title":"Epigenomics"},{"key":"ref_85","doi-asserted-by":"crossref","unstructured":"Engle, K., and Kumar, G. (2022). Cancer multidrug-resistance reversal by ABCB1 inhibition: A recent update. Eur. J. Med. Chem., 239.","DOI":"10.1016\/j.ejmech.2022.114542"},{"key":"ref_86","doi-asserted-by":"crossref","unstructured":"Niklaus, N.J., Tokarchuk, I., Zbinden, M., Schlafli, A.M., Maycotte, P., and Tschan, M.P. (2021). The Multifaceted Functions of Autophagy in Breast Cancer Development and Treatment. Cells, 10.","DOI":"10.3390\/cells10061447"},{"key":"ref_87","doi-asserted-by":"crossref","unstructured":"Ni, Y., Zhou, X., Yang, J., Shi, H., Li, H., Zhao, X., and Ma, X. (2021). The Role of Tumor-Stroma Interactions in Drug Resistance Within Tumor Microenvironment. Front. Cell Dev. Biol., 9.","DOI":"10.3389\/fcell.2021.637675"},{"key":"ref_88","doi-asserted-by":"crossref","unstructured":"Pena, L.F., Gonzalez-Andres, P., Parte, L.G., Escribano, R., Guerra, J., Barbero, A., and Lopez, E. (2023). Continuous Flow Chemistry: A Novel Technology for the Synthesis of Marine Drugs. Mar. Drugs, 21.","DOI":"10.3390\/md21070402"},{"key":"ref_89","doi-asserted-by":"crossref","unstructured":"Laughney, A.M., Kim, E., Sprachman, M.M., Miller, M.A., Kohler, R.H., Yang, K.S., Orth, J.D., Mitchison, T.J., and Weissleder, R. (2014). Single-cell pharmacokinetic imaging reveals a therapeutic strategy to overcome drug resistance to the microtubule inhibitor eribulin. Sci. Transl. Med., 6.","DOI":"10.1126\/scitranslmed.3009318"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.critrevonc.2011.03.002","article-title":"Eribulin\u2014a review of preclinical and clinical studies","volume":"81","author":"Swami","year":"2012","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"ref_91","doi-asserted-by":"crossref","unstructured":"Xu, Y., Du, X., Yu, X., Jiang, Q., Zheng, K., Xu, J., and Wang, P. (2022). Recent Advances in the Heterologous Expression of Biosynthetic Gene Clusters for Marine Natural Products. Mar. Drugs, 20.","DOI":"10.3390\/md20060341"},{"key":"ref_92","unstructured":"Singh, R.S., Singhania, R.R., Pandey, A., and Larroche, C. (2019). Metabolic Engineering of Enzyme-Regulated Bioprocesses. Advances in Enzyme Technology, Elsevier."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1038\/ja.2010.129","article-title":"Improved precursor-directed biosynthesis in E. coli via directed evolution","volume":"64","author":"Lee","year":"2011","journal-title":"J. Antibiot."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1002\/anie.202006648","article-title":"Biocatalysis: Enzymatic Synthesis for Industrial Applications","volume":"60","author":"Wu","year":"2021","journal-title":"Angew. Chem. Int. Ed. Engl."}],"container-title":["Marine Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1660-3397\/22\/9\/426\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T16:01:09Z","timestamp":1760112069000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1660-3397\/22\/9\/426"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,20]]},"references-count":94,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2024,9]]}},"alternative-id":["md22090426"],"URL":"https:\/\/doi.org\/10.3390\/md22090426","relation":{},"ISSN":["1660-3397"],"issn-type":[{"value":"1660-3397","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,20]]}}}